We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-11.95%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$545M
AUM Growth
-$226M
Cap. Flow
-$100M
Cap. Flow %
-18.35%
Top 10 Hldgs %
72.8%
Holding
51
New
4
Increased
7
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$33.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$29.4M
3
APLS
Apellis Pharmaceuticals
APLS
+$27.4M
4
BCYC
Bicycle Therapeutics
BCYC
+$15.8M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$43.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$30.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.8M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$21.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$11B
$68.8M 12.61%
1,750,000
+135,000
+8% +$5.44M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$67.8M 12.44%
1,500,000
+600,000
+67% +$27.4M
IDYA icon
3
IDEAYA Biosciences
IDYA
$3.5B
$51.8M 9.49%
3,750,000
+900,000
+32% +$10M
DSGN icon
4
Design Therapeutics
DSGN
$749M
$39.2M 7.19%
2,797,501
– –
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.72B
$30M 5.5%
+400,000
New +$29.4M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.9B
$29.2M 5.37%
300,000
-175,000
-37% -$16.2M
BCYC
7
Bicycle Therapeutics
BCYC
$275M
$28.5M 5.23%
1,700,000
+750,000
+79% +$15.8M
VTYX
8
DELISTED
Ventyx Biosciences
VTYX
$28.3M 5.19%
2,312,680
-201,600
-8% -$3.01M
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$27.9M 5.12%
+350,000
New +$33.1M
ALXO icon
10
ALX Oncology
ALXO
$281M
$25.4M 4.66%
3,136,352
+125,000
+4% +$1.36M
ARQT icon
11
Arcutis Biotherapeutics
ARQT
$3.5B
$21.3M 3.91%
1,000,000
-500,000
-33% -$10.3M
DYN icon
12
Dyne Therapeutics
DYN
$4.19B
$19.9M 3.66%
2,900,000
+165,608
+6% +$1.14M
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$19M 3.48%
150,000
-190,000
-56% -$21.8M
DICE
14
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$15.3M 2.81%
985,251
-400,000
-29% -$6.88M
OLMA icon
15
Olema Pharmaceuticals
OLMA
$1.06B
$15.2M 2.8%
3,743,875
– –
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
$14.9M 2.73%
+600,000
New +$13.2M
FULC icon
17
Fulcrum Therapeutics
FULC
$249M
$9.55M 1.75%
1,950,000
+950,000
+95% +$9.28M
ACAD icon
18
Acadia Pharmaceuticals
ACAD
$4.35B
$9.16M 1.68%
+650,000
New +$12.1M
KZR
19
DELISTED
Kezar Life Sciences
KZR
$7.86M 1.44%
95,000
-66,402
-41% -$5.86M
IPSC icon
20
Century Therapeutics
IPSC
$386M
$4M 0.73%
476,559
-73,700
-13% -$723K
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$1.95M 0.36%
399,801
-54,744
-12% -$350K
SPRB
22
Spruce Biosciences
SPRB
$122M
$1.74M 0.32%
13,333
– –
TIL icon
23
Instil Bio
TIL
$48.6M
$1.71M 0.31%
18,490
-365
-2% -$51.7K
TRML
24
DELISTED
Tourmaline Bio
TRML
$1.22M 0.22%
27,099
-3,525
-12% -$278K
EWTX icon
25
Edgewise Therapeutics
EWTX
$4.45B
$1.19M 0.22%
150,000
-63,744
-30% -$482K
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2022 Portfolio in Review

As of Q2 2022, Logos Global Management held 51 positions worth $545M, down 29% from $771M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Logos Global Management withdrew a net $100M in Q2 2022, closing 19 positions and reducing 16 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $43.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $27.9M.

  • Logos Global Management's largest Q2 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 350,000 shares worth $27.9M.
  • Logos Global Management added most to Apellis Pharmaceuticals in Q2 2022, an estimated $27.4M increase.
  • Logos Global Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $21.8M.
  • Logos Global Management fully exited Global Blood Therapeutics, Inc. in Q2 2022, selling an estimated $43.3M.
  • Logos Global Management's ten largest holdings make up 73% of its $545M portfolio in Q2 2022.
  • Logos Global Management opened 4 new positions and closed 19 in Q2 2022.
  • Logos Global Management's portfolio value fell 29% quarter-over-quarter to $545M.

Based on Logos Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.